![Yair Granot](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yair Granot
Amministratore Delegato presso Curesign Ltd
Profilo
Yair Granot is currently the Chief Executive Officer at Curesign Ltd.
Previously, he worked as the Chief Executive Officer & VP-Development at Silver Castle Holdings Ltd.
and as the Chief Technology Officer at Essence Healthcare Ltd.
He holds a doctorate degree from the University of California, Berkeley and a graduate degree from Tel-Aviv University.
Posizioni attive di Yair Granot
Società | Posizione | Inizio |
---|---|---|
Curesign Ltd
![]() Curesign Ltd Medical SpecialtiesHealth Technology Curesign Ltd is a medical device company based in Tel Aviv, Israel. The Israeli company aims to revolutionize cancer treatment by integrating advanced sensors with signal processing and big data tools to create a patient-specific treatment plan for each cancer patient. The company's product is currently in advanced stages of development and has shown successful results in preclinical studies. The CEO of the company is Yair Granot. | Amministratore Delegato | - |
Precedenti posizioni note di Yair Granot
Società | Posizione | Fine |
---|---|---|
Essence Healthcare Ltd. | Direttore Tecnico/Scientifico/R&S | - |
SILVER CASTLE HOLDINGS LTD | Amministratore Delegato | - |
Formazione di Yair Granot
University of California, Berkeley | Doctorate Degree |
Tel-Aviv University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
SILVER CASTLE HOLDINGS LTD | Health Technology |
Aziende private | 2 |
---|---|
Essence Healthcare Ltd. | |
Curesign Ltd
![]() Curesign Ltd Medical SpecialtiesHealth Technology Curesign Ltd is a medical device company based in Tel Aviv, Israel. The Israeli company aims to revolutionize cancer treatment by integrating advanced sensors with signal processing and big data tools to create a patient-specific treatment plan for each cancer patient. The company's product is currently in advanced stages of development and has shown successful results in preclinical studies. The CEO of the company is Yair Granot. | Health Technology |
- Borsa valori
- Insiders
- Yair Granot